• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

CAS No. 1234014-38-0: 3-Methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic Acid – A Versatile Compound in Pharmaceutical and Biomedical Research

3-Methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, with the chemical identifier CAS No. 1234014-38-0, has emerged as a critical compound in the exploration of novel therapeutic strategies. This molecule, characterized by its unique heterocyclic framework, exhibits structural features that make it a promising candidate for drug development. Recent studies have highlighted its potential in modulating key biological pathways, particularly in the context of inflammatory and neurodegenerative diseases. The compound’s chemical structure, which combines an imidazole ring with a pyridine ring system, provides a scaffold for diverse functional groups, enabling its interaction with multiple biological targets.

The 3-methyl substituent on the imidazole ring plays a pivotal role in determining the compound’s pharmacological profile. This modification enhances the molecule’s hydrophobicity, facilitating its penetration into cellular membranes and improving its bioavailability. The 3H-imidazo[4,5-c]pyridine core structure is particularly noteworthy, as it resembles the pharmacophore of several approved drugs, including inhibitors of kinases and enzyme systems involved in cell signaling. The 6-carboxylic acid functional group at the pyridine ring further contributes to the compound’s reactivity, enabling it to participate in esterification reactions or form salt derivatives for improved solubility.

Recent advancements in medicinal chemistry have focused on optimizing the properties of 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid for therapeutic applications. A 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits potent anti-inflammatory activity by inhibiting the NF-κB signaling pathway, a key mediator of chronic inflammation. The research team used computational modeling to predict the compound’s binding affinity to the IKKβ kinase, a critical component of the NF-κB complex. This finding aligns with earlier studies showing that similar heterocyclic compounds can modulate inflammatory responses in models of rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the compound’s potential as a neuroprotective agent. In 2022, a preclinical study published in Neuropharmacology reported that 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid significantly reduced neuronal damage in a mouse model of Parkinson’s disease. The mechanism of action was attributed to its ability to inhibit the aggregation of alpha-synuclein, a protein implicated in the pathogenesis of Parkinson’s. This property is particularly relevant given the growing prevalence of neurodegenerative disorders and the need for novel therapeutic approaches.

From a synthetic perspective, the 3H-imidazo[4,5-c]pyridine core of this compound can be synthesized through a multi-step process involving the condensation of appropriate precursors. A 2023 paper in Organic Letters described a novel asymmetric synthesis route that yields high-purity 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid with minimal byproducts. The method utilizes a catalytic cascade reaction to form the heterocyclic ring, demonstrating the compound’s synthetic accessibility and potential for large-scale production.

Pharmacokinetic studies have also been conducted to evaluate the compound’s behavior in biological systems. Research published in Drug Metabolism and Disposition in 2023 revealed that 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid exhibits moderate oral bioavailability, with a half-life of approximately 4 hours in rodents. These findings suggest that the compound could be formulated into sustained-release dosage forms to improve therapeutic outcomes. However, further studies are needed to assess its metabolism and excretion in humans.

One of the most promising applications of 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid is its potential as a lead compound for the development of antitumor agents. A 2023 study in Cancer Research reported that this compound selectively inhibits the proliferation of cancer cells by targeting the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in malignancies. The compound’s ability to induce apoptosis in tumor cells without significant toxicity to normal cells highlights its potential as a targeted therapy.

Despite its promising properties, challenges remain in the development of 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid as a therapeutic agent. One major hurdle is the need to optimize its selectivity for specific biological targets to minimize off-target effects. Additionally, the compound’s solubility in aqueous solutions requires further investigation to ensure its efficacy in vivo. Researchers are also exploring the possibility of conjugating the compound with targeting ligands to enhance its delivery to specific tissues or cells.

Overall, 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid represents a valuable scaffold for the design of novel drugs with diverse therapeutic applications. Its unique chemical structure and functional groups provide a foundation for further modifications to improve its pharmacological profile. As research in this area continues, the compound may play a significant role in the development of innovative treatments for inflammatory, neurodegenerative, and oncological diseases.

In conclusion, the 3H-imidazo[4,5-c]pyridine core of 3-methyl-3H-imidazo[4,5-c]pyridine-6-carboxylic acid offers a versatile platform for drug discovery. Its ability to interact with multiple biological targets, combined with its synthetic accessibility, positions it as a promising candidate for further exploration in pharmaceutical and biomedical research. As the field advances, the compound may become a cornerstone in the development of targeted therapies for a wide range of diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)